As part of Takeda Pharmaceuticals’ acquisition of Envoy Therapeutics Inc., the majority of Envoy scientific staff and management team will be transferred to San Diego to become part of Takeda’s Pharmaceuticals Research Division.
Osaka, Japan-based Takeda and Jupiter, Fla.-based Envoy say the terms of the projected $140 million acquisition are expected to be agreed upon within the next few days.
While the exact number of current Envoy staff members to be transferred to San Diego wasn’t made available, a press release issued by Takeda said the employees are expected to be in San Diego by next March.
Envoy is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments.
Envoy’s proprietary technology combines genetic engineering with molecular biology techniques for labeling and extracting the protein-making components of specific types of cells. The technology is especially powerful in the brain where many hundreds of cell types are intermingled, but is applicable to therapeutic areas beyond the central nervous system as well.
Takeda also gains access to Envoy’s pre-clinical CNS assets, including programs for Parkinson’s disease and cognitive impairment associated with schizophrenia.